The agreement with Axerion is the first collaboration signed within the new Neuroscience Innovative Medicines Unit that AstraZeneca announced in February 2012. Under this model, AstraZeneca and MedImmune will conduct neuroscience discovery research and early development for small and large molecules by tapping into the best available external science and sharing cost, risk and reward with other research partners active in psychiatry, neurology and pain research.
Under the terms of the agreement, Axerion has granted the AstraZeneca Neuroscience Innovative Medicines Unit an exclusive sublicense* to research, develop and commercialize a pre-clinical biologic that targets the binding of A-beta oligimers to prion proteins.
In exchange, the AstraZeneca Neuroscience Innovative Medicines Unit will provide Axerion with certain upfront and milestone payments plus research and development (R&D) funding during the time both companies are working together on the program. Additionally, Axerion will earn royalties on product sales. The financial terms of the deal have not been disclosed... Axerion Therapeutics' Press Release -
